-
Erin Sharoni, a technology platform firm, stated today, November 9, 2022, that the company’s announced his retirement as Chief Product Officer. The company’s products and services aim to address a long-standing core problem in the life insurance sector through epigenetic longevity research. The Board appreciates Erin’s leadership on the FOXO Longevity Report and wishes her continued success.
A technological platform firm called FOXO is dedicated to using products and services for the life insurance sector to commercialize longevity science. The epigenetic technology from FOXO analyzes DNA methylation using artificial intelligence to find molecular biomarkers of aging and health. By leveraging saliva-based biomarkers to streamline consumer underwriting and enhance the value of life insurance to consumers through the FOXO Longevity Report, FOXO will revolutionize the life insurance sector.
We seek to The Private Securities Litigation Reform Act of 1995’s safe harbor principles apply to certain forward-looking statements in this press release. Forward-looking statements include those about services, business strategies and plans, management’s goals for FOXO’s future operations, market size and growth prospects, competitive position, technology, and market trends.
The future intentions, plans, prospects, financial results, or strategies of FOXO and its management, the future financial condition and performance of FOXO and its products, FOXO’s market and anticipated future performance and market opportunities, are not included in these forward-looking statements.